Mandeep Takhar
Overview
Explore the profile of Mandeep Takhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1169
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ramnarine V, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, et al.
Gigascience
. 2018 May;
7(6).
PMID: 29757368
Background: Treatment-induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate-resistant prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and, for...
12.
Yang L, Roberts D, Takhar M, Erho N, Bibby B, Thiruthaneeswaran N, et al.
EBioMedicine
. 2018 May;
31:182-189.
PMID: 29729848
Background: Hypoxia is associated with a poor prognosis in prostate cancer. This work aimed to derive and validate a hypoxia-related mRNA signature for localized prostate cancer. Method: Hypoxia genes were...
13.
Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, et al.
J Cancer Res Clin Oncol
. 2018 Mar;
144(5):883-891.
PMID: 29511883
Purpose: To validate a previously characterized 10-gene signature in prostate cancer with implication to distinguish aggressive and indolent disease within low and intermediate patients' risk groups. Methods: A case-control study...
14.
Stoyanova R, Takhar M, Tschudi Y, Ford J, Solorzano G, Erho N, et al.
Transl Cancer Res
. 2017 Dec;
5(4):432-447.
PMID: 29188191
Prostate cancer exhibits intra-tumoral heterogeneity that we hypothesize to be the leading confounding factor contributing to the underperformance of the current pre-treatment clinical-pathological and genomic assessment. These limitations impose an...
15.
Liang Y, Ahmed M, Guo H, Soares F, Hua J, Gao S, et al.
Cancer Res
. 2017 Sep;
77(20):5479-5490.
PMID: 28916652
Androgen receptor (AR) signaling is a key driver of prostate cancer, and androgen-deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic disease. However, patients receiving ADT...
16.
Radtke J, Takhar M, Bonekamp D, Kesch C, Erho N, du Plessis M, et al.
Eur Urol Focus
. 2017 Jul;
4(4):540-546.
PMID: 28753844
Background: The most suspicious lesions on multiparametric magnetic resonance imaging (MRI) may be representative of final pathology. Objective: We connect imaging with high-precision spatial annotation of biopsies and genomic cancer...
17.
Urbanucci A, Barfeld S, Kytola V, Itkonen H, Coleman I, Vodak D, et al.
Cell Rep
. 2017 Jun;
19(10):2045-2059.
PMID: 28591577
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to...
18.
Kepplinger D, Takhar M, Sasaki M, Hollander Z, Smith D, McManus B, et al.
PLoS One
. 2017 Jun;
12(5):e0177569.
PMID: 28562641
The quantitation of proteins using shotgun proteomics has gained popularity in the last decades, simplifying sample handling procedures, removing extensive protein separation steps and achieving a relatively high throughput readout....
19.
Itkonen H, Brown M, Urbanucci A, Tredwell G, Lau C, Barfeld S, et al.
Oncotarget
. 2017 Apr;
8(24):38264-38275.
PMID: 28415728
Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a...
20.
Karnes R, Choeurng V, Ross A, Schaeffer E, Klein E, Freedland S, et al.
Eur Urol
. 2017 Apr;
73(2):168-175.
PMID: 28400167
Background: Risk of prostate cancer-specific mortality (PCSM) is highly variable for men with adverse pathologic features at radical prostatectomy (RP); a majority will die of other causes. Accurately stratifying PCSM...